Charak Laboratories

Charak Laboratories India Private Limited is an Indian biotechnology and pharmaceutical company focused on translational research and the development of novel therapeutics to address unmet medical needs. Led by President and Chief Medical Officer Dr. Ajay Gupta, the company is actively collaborating on the clinical development of Ramatroban, a dual thromboxane A2 and PGD2 receptor antagonist. Ramatroban is currently being evaluated in a Phase 2/Phase 3 clinical trial as an immunomodulator and antithrombotic agent for hospitalized patients with COVID-19 pneumonia. Additionally, the company aims to expand the development of Ramatroban for other indications, including viral pneumonia, silicosis, lupus nephritis, Alzheimer's disease, and cancer.